Additional serious risks include: Acute pancreatitis severe, persistent abdominal pain radiating to the back requires immediate medical attention Gallbladder disease rapid weight loss from any cause increases gallstone risk Acute kidney injury secondary to dehydration from vomiting/diarrhoea Hypoglycaemia increased risk when combined with insulin or sulfonylureas Aspiration risk during surgery delayed gastric emptying may require pre-operative fasting adjustments Contraindications Who Should Not Take Foundayo Orforglipron is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Pregnancy or planned pregnancy (discontinue at least 2 months before planned conception) Severe gastrointestinal disease including gastroparesis History of pancreatitis Type 1 diabetes Prior serious hypersensitivity reactions to any GLP-1 receptor agonist Critically, orforglipron should not be combined with other GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, or Rybelsus
He told the committee he hopes the legislation will be part of the solution to Kentuckys physician shortage
Hydration and Metabolic Changes Reduced food intake can sometimes lead to lower fluid consumption without being obvious
I hope you find my analysis more balanced if not as provocative as his
The dose itself might not change dramatically from the systemic protocol (e.g., 250-350mcg total per day), but the location of the administration is the key variable
Final Report
